AbbVie - Recruiting 18 years to 70 years. - A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
Lumena Pharmaceuticals, Inc. - Recruiting 18 years to 80 years. - A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis.
Dayanand Medical College and Hospital - Recruiting 18 years to 70 years. - Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial.
Conatus Pharmaceuticals Inc. - Recruiting 18 years or older. - A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure.
Assistance Publique - HÃ´pitaux de Paris - Recruiting 18 years to 69 years. - Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy..
Assistance Publique - HÃ´pitaux de Paris - Recruiting 18 years or older. - Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study.
Theodor Bilharz Research Institute - Recruiting 25 years to 55 years. - Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis..
University of Louisville - Recruiting 18 years to 75 years. - A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis.
Hoffmann-La Roche - Recruiting 18 years or older. - Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.
Gilead Sciences - Recruiting 18 years to 60 years. - A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety, and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2) in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH).
Leiden University Medical Center - Recruiting 18 years to 75 years. - A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy.
Salix Pharmaceuticals - Recruiting 18 years or older. - A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis.
Placebo; Rifaximin SSD 40 mg IR tablet; Rifaximin SSD 80 mg IR tablet; Rifaximin SSD 40 mg SER tablet; Rifaximin SSD 80 mg SER tablet; Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet
Merck Sharp & Dohme Corp. - Recruiting 18 years to 75 years. - A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105-00).
KT&G Life Sciences Corp - Recruiting 20 years or older. - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis.
Centre Hospitalier Universitaire Dijon - Recruiting 18 years or older. - LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedosr): Phase I Study.
AbbVie - Recruiting 18 years to 75 years. - An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Nave and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
Sequana Medical AG - Recruiting 18 years or older. - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites.
Hospital Clinic of Barcelona - Recruiting 18 years or older. - EFFICACY AND SAFETY OF SELF-EXPANDING ESOPHAGEAL STENT VERSUS ESOPHAGEAL BALLOON TAMPONADE (SENGSTAKEN TUBE) AS A RESCUE THERAPY IN VARICEAL BLEEDING REFRACTORY TO MEDICAL AND ENDOSCOPIC TREATMENT. A MULTICENTRIC, RANDOMIZED CONTROLLED TRIAL..
Asan Medical Center - Recruiting 20 years to 80 years. - Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver.
University of Padova - Recruiting 18 years to 75 years. - Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study..
terlipressin given by intravenous boluses and albumin; terlipressin given by continuous intravenous infusion and albumin
Seoul National University Hospital - Recruiting 20 years to 70 years. - Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy.
National Taiwan University Hospital - Recruiting 50 years to 70 years. - Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).
University Health Network, Toronto - Recruiting 18 years to 85 years. - Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease.